Login
Corvus Pharmaceuticals NASDAQ: CRVS
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies
| Name | Corvus Pharmaceuticals |
| Ticker | CRVS |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
|
Price
52W Low/High |
2.83
2.15 / 5.37 |
| Momentum | Sharp Down |
| Market cap | 79 M |
| 1Y Total Return |
21.46%
Below Average |
| 1Y Volatility |
101.35%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies
Details
| Ticker | CRVS |
| Name | Corvus Pharmaceuticals |
| ISIN | US2210151005 |
| CUSIP | |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 4/14/21
| Close Price | 2.83 |
| 52W Low/High | 2.15 / 5.37 |
| Market cap | 79 M |
| 1Y Total Return |
21.46%
Below Average |
| 1Y Volatility |
101.35%
High Risk |
| Beta | 2.29 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | - |
| Cash from Op. / Cur. Liabilities | -2.86 |
| Diluted Earnings / Share | -0.20 |
| ROE | - |
| ROIC | -9.6% |
| Price / Revenue | - |
| Price / Book | 1.2 |
| Price / CF | -2.4 |
| Current Ratio | 3.7 |
| Cur.Liabilities / Tot.Liabilities | 0.9 |
| Financial Leverage | 0.03 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gross Profit |
-
|
-
|
-
|
-
|
-
|
-
|
|
| R&D |
32
|
38
|
39
|
46
|
29
|
11
|
|
| EBITDA |
-5
|
-46
|
-46
|
-55
|
-36
|
-31
|
|
| Operating Income |
-44
|
-49
|
-49
|
-57
|
-37
|
-14
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
29
|
29
|
28
|
20
|
15
|
0
|
|
| EPS exc. Extra |
-0.20
|
-1.59
|
-1.71
|
-2.72
|
-2.36
|
-83.86
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
86
|
84
|
118
|
95
|
140
|
98
|
|
| Cash, Eq & Invt ShortTerm |
44
|
78
|
115
|
90
|
135
|
94
|
|
| Total Current Assets |
45
|
79
|
116
|
91
|
136
|
96
|
|
| Total Non-Current Assets |
40
|
4
|
3
|
4
|
4
|
3
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
13
|
13
|
8
|
10
|
7
|
4
|
|
| Total Current Liabilities |
12
|
10
|
7
|
9
|
6
|
3
|
|
| Long Term Debt |
1
|
2
|
1
|
1
|
1
|
1
|
|
| Shareholder equity |
72
|
71
|
110
|
85
|
133
|
-31
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-35
|
-37
|
-41
|
-46
|
-28
|
-11
|
|
| Depreciation |
1
|
1
|
1
|
1
|
1
|
0
|
|
| Cash from Investing |
45
|
3
|
-30
|
85
|
-43
|
-92
|
|
| Capex |
0
|
0
|
0
|
0
|
2
|
2
|
|
| Cash from Financing |
1
|
0
|
65
|
1
|
71
|
95
|
|
| Stock Issued |
1
|
0
|
65
|
1
|
71
|
0
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
42
|
-40
|
-79
|
33
|
-75
|
-123
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
3.7
|
7.8
|
16.4
|
10.2
|
22.9
|
31.2
|
|
| Financial Leverage D/E |
0.03
|
0.04
|
0.00
|
0.00
|
0.00
|
-
|
|
| Return on Capital Avg |
-9.6%
|
-66.5%
|
-83.3%
|
-65.5%
|
-33.0%
|
-70.7%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available